Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

OTHER 14 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3214 Carcinoma, Non-Small-Cell Lung 2727 Breast Neoplasms 2550 Colorectal Neoplasms 1461 Prostatic Neoplasms 1307 Neoplasm Metastasis 1300 Multiple Myeloma 1112 Melanoma 1103 Ovarian Neoplasms 1006 Lung Neoplasms 944 Recurrence 924 Leukemia, Myeloid, Acute 879 Pancreatic Neoplasms 832 Lymphoma, Non-Hodgkin 767 Lymphoma 713 Stomach Neoplasms 692 Carcinoma, Renal Cell 660 Carcinoma, Hepatocellular 647 Leukemia, Lymphocytic, Chronic, B-Cell 560 Squamous Cell Carcinoma of Head and Neck 550 Lymphoma, Follicular 515 Head and Neck Neoplasms 490 Glioblastoma 472 Small Cell Lung Carcinoma 447 Lymphoma, Large B-Cell, Diffuse 440 Triple Negative Breast Neoplasms 435 Advanced Solid Tumors 432 Leukemia 426 Uterine Cervical Neoplasms 420 Urinary Bladder Neoplasms 405

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hemangioma, Cavernous, Central Nervous System × Clear all

NCT05085561 2025-08-06

SYCAMORE

Recursion Pharmaceuticals Inc.

Phase 2 Completed

Hemangioma, Cavernous, Central Nervous System

Data powered by HemOnc (CC BY 4.0) Colophon ⚡